• Home
  • Journalists
    • Headlines
  • Community
    • Businesses
    • Jobs
    • Learning
    • Marketplace
  • Store
(@)

Eli Lilly Trial Finds Alzheimer’s Drug Can Slow Progress of Disease

Donanemab is not a cure and comes with significant side effects, but patients had longer periods of independent living while on the drug.

Gina Kolata
Author: Gina Kolata

Written by

Gina Kolata

in

Drugs (Pharmaceuticals), Eli Lilly and Company, Research
←FTC Seeks ‘Blanket’ Ban on Meta’s Use of Young Users’ Data
Trump’s New Anti-Biden Ad Has One Problem: It Shows Photos From His Own Presidency→

More posts

  • WATCH: Gen Z turn to ‘grandma hobbies’ to fight screen time

  • Oil Falls and Stocks Rise After a Day of Drastic Swings

  • Gas Prices Hit $3.54 a Gallon, Up 19% Since Attacks on Iran

  • F.A.A. Briefly Halts JetBlue Departures After System Outage

About Us


Support Us

Trademark & Copyright 1998 – 2025 · MOSAEC

  • Facebook
  • Instagram
  • LinkedIn
  • YouTube